Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280898 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2FFAR4 | |
| SCHEMBL5287636 | 0.79 | RAB9A (0.41) | SLC6A2SLC6A4SLC6A3LMNARAB9A | |
| SCHEMBL6038064 | 0.78 | LMNA (0.49) | LMNAEPHX2RAB9AMEN1KMT2A | |
| SCHEMBL5325209 | 0.78 | LMNA (0.51) | LMNAEPHX2RAB9AMEN1KMT2A | |
| SCHEMBL5280502 | 0.77 | RAB9A (0.44) | SLC6A2SLC6A4SLC6A3LMNARAB9A | |
| SCHEMBL6037915 | 0.77 | LMNA (0.50) | LMNAEPHX2RAB9AMEN1KMT2A | |
| SCHEMBL5278232 | 0.76 | CCR1 (0.42) | FFAR4EPHX2CCR1 | |
| SCHEMBL5278229 | 0.76 | CCR1 (0.42) | FFAR4EPHX2CCR1 | |
| SCHEMBL5286937 | 0.76 | CCR1 (0.42) | FFAR4EPHX2CCR1 | |
| SCHEMBL5277774 | 0.76 | LMNA (0.51) | LMNAEPHX2RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | SLC6A2 4450/4885SLC6A4 4364/4885SLC6A3 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.